Xenon Pharmaceuticals Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

XENE$41.39+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in thousands of U.S. dollars except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue (note 9)	$—	$—	$—	$7,500
Operating expenses:
Research and development	99,224	74,985	187,732	136,185
General and administrative	23,931	19,244	47,751	38,282
Total operating expenses	123,155	94,229	235,483	174,467
Loss from operations	(123,155)	(94,229)	(235,483)	(166,967)
Other income:
Interest income	12,145	7,199	19,052	15,282
Foreign exchange gain (loss)	(311)	1,698	237	1,733
Total other income	11,834	8,897	19,289	17,015
Loss before income taxes	(111,321)	(85,332)	(216,194)	(149,952)
Income tax recovery	585	626	3,156	199
Net loss	$(110,736)	$(84,706)	$(213,038)	$(149,753)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities (note 5)	(1,445)	949	(2,991)	1,725
Comprehensive loss	$(112,181)	$(83,757)	$(216,029)	$(148,028)
Net loss per common share (note 10):
Basic and diluted	$(1.11)	$(1.07)	$(2.28)	$(1.90)
Weighted-average common shares outstanding (note 10):
Basic and diluted	99,609,804	78,953,445	93,477,761	78,820,474

-4-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.